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Renoprotective effects of losartan in diabetic nephropathy: Diabetic nephropathy is a serious long-term complica-
Interaction with ACE insertion/deletion genotype? tion of diabetes mellitus that develops in 30 to 40% of
Background. The beneficial short- and long-term renopro- patients with type 1 diabetes [1]. In recent years a vast
tective effects of angiotensin I-converting enzyme (ACE) inhi- number of studies have investigated the association be-bition are lower in albuminuric diabetic patients homozygous
tween the insertion/deletion (I/D) polymorphism of thefor the deletion compared to the insertion polymorphism of
gene coding for angiotensin converting enzyme in thethe ACE gene. In an attempt to overcome this interaction,
development [2] and progression of diabetic and non-we evaluated the short-term renoprotective effect in diabetic
nephropathy of the angiotensin II receptor antagonist losartan diabetic kidney disease [3–13].
in patients homozygous for the insertion or the deletion allele. Intervention trials have suggested that angiotensin I-con-
Methods. Fifty-four hypertensive type 1 diabetic patients with verting enzyme (ACE) inhibitors can retard the progres-
diabetic nephropathy homozygous for the insertion (I; N 26) sion of diabetic renal disease in a manner that may in partor the deletion (D; N 28) allele of the ACE/ID polymorphism
be independent of their effects on arterial blood pressurewere included. After four weeks of washout, the patients re-
[14]. However, short-term (antiproteinuric) and long-termceived losartan 50 mg daily followed by 100 mg in two treatment
(GFR progression) renoprotective effects of ACE inhibi-periods each lasting two months. Patients and investigators
were blinded to ACE genotypes. At baseline and in the end tion treatment vary considerably between patients, which
of the treatment periods, 24-hour blood pressure, albuminuria suggests the involvement of genetic factors [15].
and glomerular filtration rate values were determined. The ACE/ID polymorphism has been suggested to
Results. At baseline, blood pressure, albuminuria and glomer- play an important role in the individual antiproteinuric
ular filtration rate (GFR) values were similar in the two geno-
response to ACE inhibition, even though the data con-type groups [II vs. DD, 1134 (238 to 5302) vs. 1451 (227 to
flict [3–6, 16–18]. Patients homozygous for the D allele8129) mg/24 h, median (range); 156/82 (17/9) vs. 153/80
are characterized by elevated levels of ACE compared(17/11) mm Hg, mean (SD); and 86 (22) vs. 88 (24) mL/min/1.73
m2, respectively]. Both doses of losartan significantly lowered to patients homozygous for the I allele, which might
blood pressure, albuminuria, and GFR (P  0.05 vs. baseline). explain the diversity in the response to ACE inhibition
Losartan 100 mg was more effective than 50 mg in reducing [19, 20]. A reduced antiproteinuric effect of ACE inhibi-
albuminuria, 51% (95% CI; 40 to 61) versus 33% (23 to 42), tion was found in diabetic patients homozygous for the
respectively (P 0.01). No differences in the impact of losartan D allele [6, 16, 21], suggestive of a reduced long-termbetween the II and DD groups were observed: Losartan 100
renoprotective effect as demonstrated in non-diabeticmg lowered systolic/diastolic blood pressure by 12/6 and 10/4
kidney disease [3]. However, specific blockade of themm Hg, whereas albuminuria decreased by 55% (35 to 68)
angiotensin II subtype 1(AT1) receptor would be ex-and 46% (28 to 61), in the II and DD groups, respectively
(P  NS). pected to overcome the interaction between the ACE/ID
Conclusion. Our data suggest that losartan offers similar genotype and ACE inhibition, and consequently induce
short-term renoprotective and blood pressure lowering effects similar antiproteinuric effects in both genotype groups.
in albuminuric hypertensive type 1 diabetic patients with the Therefore, we performed a study to evaluate the short-ACE II and DD genotypes. However, the long-term renopro-
term renoprotective effect of AT1 receptor antagonismtective effects remain to be evaluated.
in hypertensive type 1 diabetic patients with diabetic
nephropathy homozygous for the D or I allele.
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polymorphism were included from the registry of type 1 using the patients surface area at the start of the study.
The mean coefficient of variation in GFR of each patientdiabetic patients suffering from diabetic nephropathy at
from day to day was 4%.the Steno Diabetes Center. Patients and investigators
Albuminuria was determined as the geometric meanwere blinded to ACE/ID genotypes, except one (LT),
of at least two consecutive 24-hour urine collections,who had knowledge of genotypes and selected the homo-
completed immediately before each visit (Turbidimetry,zygous patients from the registry in order to secure
Cobas Mira Plus; Roche, Mannheim, Germany). Urinaryequality between numbers of patients and baseline char-
excretion of sodium and urea (Cobas Mira Plus; Roche)acteristics in each genotype group. Two patients were
were measured from all urine collections. The excretionexcluded during the study, one because of malignant
of urea was used to calculate the protein intake fromdisease and one due to heart failure requiring ACE inhi-
the nitrogen content of the urea and an estimated valuebition. Compliance was assessed by pill counts. Patients
of non-urea nitrogen of 31 mg · kg1 · day1 [29]. Urinarywere to be excluded from the study if compliance was less
excretion of IgG was determined by enzyme-linked im-than 85%. All patients fulfilled the compliance criteria.
munosorbent assay (ELISA) [30] from the urine col-Fifty-four patients homozygous for the D (N  28) or I
lected during GFR determinations.(N 26) allele of the ACE/ID polymorphism completed
From venous blood samples, serum potassium, sodium,the study.
creatinine, cholesterol concentrations were determinedDiabetic nephropathy was diagnosed clinically in pa-
(Cobas Mira Plus; Roche) and hemoglobin A1C (HbA1c)tients with persistent albuminuria (300 mg/24 h), dia-
measured by high-performance liquid chromatographybetic retinopathy, and absence of other evidence of kid-
(HPLC; normal range 4.1 to 6.4%; Variant; Biorad Labo-ney or renal tract disease [22]. Fifty-two patients received
ratories, Munich, Germany). Blood samples for determi-antihypertensive medication prior to the study; 42 were
nation of angiotensin II levels were drawn in prechilledtreated with ACE inhibitors and 10 with calcium an-
tubes after 30 minutes of supine rest and immediatelytagonists. Before enrollment all antihypertensive medi-
centrifuged at 4C, and plasma concentrations were mea-cation was withdrawn for at least four weeks. A period
sured radioimmunologically [31]. Renin concentrationsof four weeks was applied based on evidence from previ-
in plasma were determined according to the method ofous clinical and pharmacokinetic studies [23, 24]. All
Deinum, Derkx, and Schalekamp [32].patients fulfilled the following inclusion criteria: Diabetic
Blood pressure values are based on 24-hour ambula-nephropathy, GFR 60 mL/min/1.73 m2, office blood
tory blood pressure measurements performed with thepressure 135/85 mm Hg and age between 18 and 70
Takeda TM2420 (version 7; A&D, Tokyo, Japan) device.years. Patients were excluded if they had a history of
Blood pressures were measured every 15 minutes duringmalignant hypertension, congestive heart failure, myo-
the day (7:00 am to 11:00 pm) and every 30 minutes duringcardial infarction or stroke within the last three months.
night (11:00 pm to 07:00 am). Values were averaged forDietary intake of protein or salt was not restricted. The
each hour before calculating the 24-hour blood pressure.study was performed according to the principles of the
Declaration of Helsinki and approved by the ethical Data analysis
committee of Copenhagen County. All patients gave
Data are expressed as means SD and means SEMtheir informed consent.
except for albuminuria and fractional clearance of IgG,Our study consisted of two treatment periods each
renin, angiotensin II and aldosterone, which were loga-lasting two months. The patients received two doses of
rithmically transformed before statistical analysis owinglosartan, that is, losartan 50 mg daily in the first two
to their skewed distribution, and are given as the geomet-months, followed by 100 mg daily in the second period as
ric means (95% CI). Albuminuria is expressed as theopen label treatment. At baseline and at the end of each
median and range in the abstract and Table 1. Data were
two-month treatment period, 24-hour blood pressure,
analyzed by analysis of variance (ANOVA) according
proteinuria and GFR were determined. Patients and the to a general linear model, repeated measures method.
investigator were blinded to the ACE/ID genotypes. Results from the end of each treatment period were
compared with baseline data. Subsequently, intergroupLaboratory procedures
comparisons were performed with the two-sided Student
The ACE/ID genotyping was performed by polymer- t test. A P value 0.05 was considered significant (two
ase chain reaction (PCR) [25, 26]. tailed). Data were analyzed using the SPSS 10.0 software
Glomerular filtration rate was measured after a single program (SPSS Inc., Chicago, IL, USA).
intravenous injection of 3.7 MBq 51Cr-ethylenediamine-
tetraacetic acid (EDTA) at 8.00 am by determining the
RESULTSradioactivity in venous blood samples taken 180, 200,
220 and 240 minutes after the injection [27, 28]. The Baseline clinical characteristics did not differ signifi-
cantly by ACE genotype, apart from serum ACE concen-results were standardized for 1.73 m2 body surface area,
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Table 1. Baseline characteristics of 54 hypertensive type 1 (P  0.05). Levels of hormones in the renin angiotensin
diabetic patients with diabetic nephropathy and homozygosity for
aldosterone system (RAAS) are given in Table 3. Asthe I (N  26) or D (N  28) allele of the ACE/ID polymorphism
expected, ACE levels were significantly higher in the
ACE genotype patients homozygous for the D allele, but remained un-
II DD changed in both treatment periods. Renin and angioten-
Sex male/female 16/10 17/11 sin II increased similarly in the II and DD groups during
Age years 4410 458 the losartan treatment, and most during the high dose
Diabetes duration years 348 3310
period compared to losartan 50 mg period. A significantDuration of nephropathy years 127 126
Retinopathy dose-independent increase in HbA1c from baseline was
(simplex/proliferative) % 12/88 25/75 observed in both groups (P 0.05; Table 3). Serum cho-
Albuminuriaa mg/24 hr 1134 (238–5302) 1451 (227–8129)
lesterol was marginally reduced in both groups by lo-24-hour Systolic BP mm Hg 15317 15317
24-hour Diastolic BP mm Hg 829 8011 sartan 100 mg, while high density lipoprotein (HDL)
Glomerular filtration rate cholesterol, potassium, sodium, creatinine, dietary pro-
mL/min/1.73 m2 8622 8824
tein intake and urinary sodium excretion remained un-
Data are mean  SD or a median (range)
changed (Table 3).
Table 4 compares patients with an albuminuria reduc-
tion above the median (high responders) to those with
a reduction below the median (low responders). Thetration (Table 1). Twelve patients, equally distributed
between the two genotypes (4 II/8 DD, NS), received patients on diuretic treatment were equally distributed
between groups. No differences were detected at base-diuretic treatment during the whole study to treat edema
(thiazides N 4, furosemide N 8). No other concomi- line, but the high responder group had an enhanced rise
in serum renin (P  0.05) and a tendency of a largertant antihypertensive treatment was given. Two patients
reported orthostatic vertigo in the high dose period, but reduction in systolic blood pressure (P 0.08) compared
no other side effects related to the study medication to the low responders.
were registered.
Losartan significantly reduced arterial blood pressure,
DISCUSSIONalbuminuria, fractional clearance of albumin and IgG
Our double-blind prospective trial demonstrates thatand compared to baseline (Table 2). No significant influ-
the short-term renoprotective capacity of angiotensin IIence of the ACE/ID genotype on the antiproteinuric
subtype 1 (AT1) receptor antagonism in diabetic ne-effect of losartan treatment was found: Losartan 100 mg
phropathy is similar in type 1 diabetic patients with ACEdaily lowered albuminuria by 55% (range, 35 to 68; P 
(AT1) II and DD genotypes. Losartan had a beneficial0.01) in the II group and 46% (28 to 61; P  0.01) in the
effect on cardiovascular risk profile, as reflected by re-DD group, respectively, corresponding to a difference be-
duction in arterial blood pressure, albuminuria and se-tween groups of 9% (18 to 25; NS). In parallel, frac-
rum cholesterol concentration. It is well known fromtional clearance of albumin decreased by 47% (27 to 62;
studies in both diabetic and non-diabetic albuminuricP  0.01) and 36% (20 to 49; P  0.05), fractional clear-
renal disease that an effective short-term response, thatance of IgG by 56% (11 to 79; P  0.05), and 42% (22
is, a reduction in albuminuria after initiation of antihy-to 57; P 0.05), respectively (NS between groups). Anal-
pertensive treatment, is a strong predictor of subsequentysis of the data leaving out patients on diuretic treatment,
long-term renoprotective capacity of slowing progressiondemonstrated a reduction in albuminuria by losartan 100
in kidney function [33, 34]. Reduction in albuminuriamg of 50% (31 to 64) in the II group and 42% (17
was larger during high dose treatment, in keeping withto 59) in the DD group without significant differences
recent data from our group [abstract; Andersen, Diabe-between groups. Considering the total cohort, losartan
tologia 43(Suppl 1), 2000]. Previous studies have demon-100 mg was significantly more effective in reducing albu-
strated that the maximal antiproteinuric and antihyper-minuria compared to 50 mg (P  0.01). Losartan 100
tensive effect by losartan is reached after three to fourmg lowered albuminuria by 65% (28 to 83; P  0.01) in
weeks of treatment (abstract; Preti et al, Am J Hypertensthe 12 patients receiving diuretics, compared to 46%
11, 1998) [35], ruling out the possible influence of a car-(33 to 57; P  0.01) in the 42 patients without diuretic
ryover effect. Furthermore, a recent randomized double-treatment. The difference between the diuretic and non-
blind crossover trial, in which study medication was givendiuretic group showed a tendency for statistical signifi-
in random order, demonstrated that the magnitude ofcance (P 0.1), though the numbers applied were small.
the reductions in blood pressure and albuminuria byLosartan 50 and 100 mg significantly lowered systolic
losartan 50 and 100 mg were independent of order ofand diastolic blood pressures from baseline without in-
treatment periods [36].tergroup differences (Table 2). GFR declined by 4 and
5 mL/min/1.73 m2 in the II and DD groups, respectively The influence of sodium status and diuretic treatment
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Table 2. Kidney function and blood pressure in hypertensive type 1 diabetic patients with diabetic nephropathy and
homozygosity for the I (N  26) or D (N  28) allele of the ACE/ID polymorphism
Baseline Losartan 50 mg Losartan 100 mg
ACE genotype II DD II DD II DD
Albuminuria mg/24 h 1123 (821–1537) 1210 (886–1655) 755b (511–1115) 802b (558–1152) 508b (314–820) 645b (434–959)
Albumin clearance/GFR(10–6) 309 (205–465) 332 (223–495) 214b (133–345) 219b (137–351) 162b (94–281) 212b (135–333)
IgG clearance/GFR(10 –6) 101 (62–164) 138 (88–215) 70b (48–103) 85b (51–144) 46b (23–93) 80b (52–123)
GFRa mL/min/1.73 m2 864 884 844b 844b 814b 844b
24-hour Systolic BPa mm Hg 1563 1533 1453b 1453b 1444b 1434b
24-hour Diastolic BPa mm Hg 822 802 772b 762b 762b 762b
Geometric mean (95% CI) or a mean  SE
b P  0.05 vs. baseline
Table 3. Laboratory data in hypertensive type 1 diabetic patients with diabetic nephropathy and homozygosity
for the I (N  26) or D (N  28) allele of the ACE/ID polymorphism
Baseline Losartan 50 mg Losartan 100 mg
ACE genotype II DD II DD II DD
Serum renina lU/mL 401 381 491b 571b 691b 721b
Serum ACEa IU/L 171 251c 161 241c 171 241c
Plasma angiotensin IIa pmol/L 81 121 151 171 211b 221b
Plasma aldosteronea pg/mL 671 861 631 791 531 661
Serum potassium mmol/L 4.20.1 4.20.1 4.20.1 4.30.1 4.20.1 4.40.1
Serum sodium mmol/L 1411 1401 1401 1391 1401 1391
Serum cholesterol mmol/L 5.00.1 5.40.2 5.00.1 5.20.2 4.90.2b 5.10.2b
Serum HDL-cholesterol mmol/L 1.60.1 1.60.1 1.60.1 1.60.1 1.60.1 1.60.1
HbA1c % 8.70.2 9.00.2 9.20.2b 9.40.2b 9.00.2b 9.50.2b
Serum creatinine lmol/L 1034 1077 1034 1108 1054 1118
Dietary protein intake g/kg/24 h 1.20.1 1.00.1 1.10.1 1.00.1 1.00.1 1.00.1
Urinary sodium mmol/24 h 1629 13911 16815 15911 15512 15615
Data are mean  SE or a geometric mean  SE
b P  0.05 vs. baseline
c P  0.05 II vs. DD
Table 4. Baseline values and responses to losartan 100 mg separated by the median in hypertensive type 1
diabetic patients with diabetic nephropathy
Reduction in albuminuria median Reduction in albuminuria median
Group 1 (N  27) (II/DD 13/14) Group 2 (N  27) (II/DD 13/14)
Parameter Baseline Losartan 100 mg Baseline Losartan 100 mg
Albuminuriaa mg/24 h 1141 (802–1622) 966 (682–1370) 1196 (883–1619) 342 (215–545)c
GFR mL/min/1.73 m2 884 854 865 804
24-hour Systolic BP mg Hg 1573 1493 1533 1384d
24-hour Diastolic BP mg Hg 812 772 802 742
Serum cholesterol mmol/L 5.30.2 5.10.2 5.20.2 4.80.2
Serum reninb lU/mL 401 561 391 891c
Plasma angiotensin IIb pmol/L 91 181 111 251
Urinary sodium mmol/24 h 14712 16918 15210 15112
Data are mean  SE, a geometric mean (95% CI), or b geometric mean  SE
c P  0.05, response to treatment Group 1 vs. Group 2
d P  0.08, response to treatment Group 1 vs. Group 2
on the efficacy of blockade of the RAAS is well estab- Our short-term pilot study of a limited number of pa-
tients cannot completely exclude a possibility of an in-lished. However, leaving out the 12 patients on diuretic
treatment from the analysis did not change the interpre- fluence of the ACE/ID genotype on the albumin low-
ering effect of angiotensin II receptor antagonism. How-tation of the study. Moreover, separation of data by the
median of 24-hour sodium excretion rates in separate ever, with 95% confidence we are able to exclude a
difference of more than 18 or 25%. To exclude agenotype groups does not reveal any indications of inter-
actions between sodium status and ACE genotype to 5 or 10% difference with 90% power would, with the
observed variability in albuminuria, require 1089 or 272therapy response.
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patients in each genotype group, respectively. Therefore, is associated with an increased risk of renal function loss
[3–13]. These data are supported by recent morphologi-larger and long-term studies must be performed to con-
firm or reject the conclusions from the present data. cal studies of progression of diabetic glomerulopathy
(abstract; Solini et al, Diabetologia 43(Suppl 1), 2000)The renoprotective findings of losartan treatment are
potentially a clinically important step forward compared [40]. Patients with DD genotype are characterized by
elevated levels of ACE that may be crucial for the reno-to ACE inhibition, since influence of the ACE/ID geno-
type is eliminated. This interpretation assumes otherwise protective effect of ACE inhibitor treatment [19]. Previ-
ous studies in non-diabetic proteinuric renal diseaseequal efficacy and side effect profiles for the two classes
of compounds, as discussed below. reached conflicting results regarding the ACE/ID poly-
morphism and susceptibility to ACE inhibition [3, 4, 17,Two previous studies in diabetic and non-diabetic ne-
phropathies in cohorts not stratified for genotypes have 18, 41]. In diabetes, we have previously demonstrated
that homozygosity for the D allele reduces the long-termcompared the renoprotective effects of losartan 100 mg
and enalapril 20 mg [23, 36]. Both studies demonstrated beneficial effect of ACE inhibition on the progression
of diabetic nephropathy in type 1 diabetic patients [5].an approximately 50% reduction in albuminuria for both
compounds; thus, the magnitude of the albumin lowering Moreover, it has been shown that diabetic patients ho-
mozygous for the I allele are more susceptible to ACEeffects in the present study with patients homozygous
for II and DD genotypes are equivalent to the effect of inhibitor treatment compared to the D allele [6, 16].
Since ACE genotypes not only influence the responsehigh dose ACE inhibition in cohorts with mixed geno-
types. In a previous retrospective study we investigated to therapy, but probably also affect the progression of
kidney disease, it may be difficult to distinguish the thera-the reduction in albuminuria after initiation of ACE
inhibitor treatment in patients with different ACE I/D peutic response to ACE inhibition and the natural course
of the disease. The natural course of diabetic nephropa-genotypes [16]. In the II patients, albuminuria was re-
duced by 61%, while the effect of ACE inhibition was thy in type 1 diabetic patients separated into different
ACE I/D genotypes has only been described in normo-only 31% in the DD patients (P  0.01 II vs. DD).
Comparisons of data with results from the present pro- tensive patients [42]. No differences were found between
the rate of decline in GFR in the II and DD genotypes,spective study must be carried out with extreme caution
due to the different study designs. However, the data but the reduction in GFR was below 2 mL/min/year in
both groups. Similar data for the natural course of dia-suggest a more pronounced antiproteinuric effect of AT1
receptor blockade in DD patients. However, suggestions betic nephropathy in hypertensive subjects such as the
participants in the present study do not exist.of selective beneficial therapy for different genotypes
require a head-to-head comparison of ACE inhibition A possible role for the deleterious effect of the D allele
on kidney function in diabetic nephropathy may be re-and AT1 receptor blockade, which was not done in the
present study. lated to increased angiotensin II formation. Blockade of
the AT1 receptor would be expected to overcome theAngiotensin converting enzyme plays an important
role in the conversion of angiotensin I to the potent interaction between the ACE/ID polymorphism and ele-
vated ACE concentration. However, numbers of AT1vasoconstrictor angiotensin II. Consequently, inhibition
of ACE reduces the formation of angiotensin II with a receptors could be up-regulated and thereby reduce the
beneficial effect of AT1 receptor antagonism in patientscompensatory increase in serum renin [23]. As expected,
levels of ACE in patients with DD genotype were ele- with high ACE and subsequent high angiotensin II levels.
In our study, levels of circulating angiotensin II werevated in our study, while baseline levels of renin, angio-
tensin II and aldosterone were similar in both genotype similar in the II and DD groups, but locally elevated
angiotensin II within organs or endothelial cells may begroups in accordance with previous data [37]. Renin and
angiotensin II increased similarly in both genotype associated with the D allele.
Hemoglobin A1c was significantly increased after initi-groups, which is consistent with our findings in previous
studies on the blockade of the AT1 receptor in mixed ation of the study drug without changes in body weight
or insulin doses during the study (Table 3). Previously,genotypes [36, 38]. Thus, the elevated ACE level in DD
patients had no impact on the other systemic RAAS it has been suggested by Marre et al that the acute renal
effects of hyperglycemia are influenced by the ACE/IDhormones at baseline or during AT1 receptor blockade.
However, previous experimental and functional studies genotype [43]. In normoalbuminuric type 1 diabetic pa-
tients carrying one or two D alleles they found a preglo-have demonstrated an enhanced vascular conversion of
angiotensin I to angiotensin II in the DD compared to merular vasodilation during hyperglycemia, which was
not found in II patients. The absence of vasodilationthe II genotype (abstract; Chang et al, J Am Soc Nephrol
9:1705A, 1998) [39]. during acute hyperglycemia is suggested as being a pro-
tective mechanism in II patients. However, the elevatedSeveral longitudinal follow-up studies in diabetic and
non-diabetic kidney disease have found that the D allele HbA1c levels in our study reflect long-term effects, and
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